Actively Recruiting
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Led by MiraKind · Updated on 2025-01-23
15000
Participants Needed
1
Research Sites
1095 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
CONDITIONS
Official Title
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Personal or family history of cancer
- Personal history of endometriosis, or autoimmunity
You will not qualify if you...
- Younger than 18 years old
- Non-English speaking and unable to understand and sign the consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MiraKind
Los Angeles, California, United States, 90025
Actively Recruiting
Research Team
J
Joanne Weidhaas, MDPhD
CONTACT
J
Joanne Weidhaas
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here